Oakland Southfield Physicians

OSP News

Diabetes Medications with FDA-Approved Cardiovascular Indication

Posted: 02/25/2020

Studies from diabetes medications within two drug classes, SGLT-2 inhibitors and GLP-1 agonists, have proven these medications can be used for cardiovascular risk reduction. Below is the list of drugs and their individual cardiovascular indications.

SGLT-2 Inhibitors

  • Jardiance (empagliflozin)
    • To reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease
  • Invokana (canagliflozin)
    • To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease
    • To reduce the risk of end-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria
  • Farxiga (dapagliflozin)
    • To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and established cardiovascular disease or multiple cardiovascular risk factors

GLP-1 Agonists

  • Victoza (liraglutide)
    • To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease
  • Ozempic (semaglutide)
    • To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease
  • Trulicity (dulaglutide)
    • To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus with and without established cardiovascular disease

We value your privacy. We use cookies and other technologies to keep the web site reliable and secure, tailor your experience, and measure web site performance, as described in our Privacy Policy.

x

OSP Technical Support